HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Abstract
All of the cases of medullary thyroid carcinoma (MTC) express the RET receptor tyrosine kinase. In essentially all of the hereditary cases and approximately 40% of the sporadic cases of MTC, the RET kinase is constitutively activated by mutation. This suggests that RET may be an effective therapeutic target for treatment of MTC. We show that the indolocarbazole derivatives, CEP-701 and CEP-751, inhibit RET in MTC cells. These compounds effectively inhibit RET phosphorylation in a dose-dependent manner at concentrations <100 nM in 0.5% serum and at somewhat higher concentrations in the presence of 16% serum. They also blocked the growth of these MTC cells in culture. CEP-751 and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell xenografts. These results show that inhibiting RET can block the growth of MTC cells and may have a therapeutic benefit in MTC.
AuthorsChristopher J Strock, Jong-In Park, Mark Rosen, Craig Dionne, Bruce Ruggeri, Susan Jones-Bolin, Samuel R Denmeade, Douglas W Ball, Barry D Nelkin
JournalCancer research (Cancer Res) Vol. 63 Issue 17 Pg. 5559-63 (Sep 01 2003) ISSN: 0008-5472 [Print] United States
PMID14500395 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • CEP 751
  • Carbazoles
  • Enzyme Inhibitors
  • Furans
  • Growth Inhibitors
  • Indoles
  • Oncogene Proteins
  • Prodrugs
  • lestaurtinib
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • Receptor Protein-Tyrosine Kinases
Topics
  • Animals
  • Carbazoles (pharmacology)
  • Carcinoma, Medullary (drug therapy, enzymology, pathology)
  • Cell Division (drug effects)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (pharmacology)
  • Furans
  • Growth Inhibitors (pharmacology)
  • Humans
  • Indoles
  • Male
  • Mice
  • Mice, Nude
  • Multiple Endocrine Neoplasia Type 2b (genetics)
  • Mutation
  • Oncogene Proteins (antagonists & inhibitors, metabolism)
  • Phosphorylation (drug effects)
  • Prodrugs (pharmacology)
  • Proto-Oncogene Proteins c-ret
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism)
  • Thyroid Neoplasms (drug therapy, enzymology, pathology)
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: